Abstracts tagged "Disease Activity"

Abstract Number: 2967 • 2014 ACR/ARHP Annual Meeting
Patient Reported Pain By the Paindetect Questionnaire Reveals Multimodal Elements to Pain Perception in Rheumatoid Arthritis
Saqa Ahmed¹, Tejal Magan¹, Mario Vargas¹, Abiola Harrison¹ and Nidhi Sofat², ¹Rheumatology, Mailpoint J1A, St George's, University of London, London, United Kingdom, ²Rheumatology, St. George's University of London, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted towards synovial joints. Inhibition of pro-inflammatory networks by disease-modifying anti-rheumatic drugs…
Abstract Number: 2615 • 2014 ACR/ARHP Annual Meeting
Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis
Walter P. Maksymowych¹, Stephanie Wichuk¹, P. Scott Eastman² and Eric H. Sasso³, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Crescendo Bioscience, Inc., South San Francisco, CA, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose There has been limited validation of soluble biomarker measures of disease activity in patients with axial spondyloarthritis (SpA). C-reactive protein (CRP) is most commonly…
Abstract Number: 2379 • 2014 ACR/ARHP Annual Meeting
Minimal Radiographic Progression in RA Patients Receiving Routine Care in the Espoir Early Arthritis Cohort: Similar Prognosis According to 6 Different Remission Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Université Paris René Descartes and Hôpital Cochin, Paris, France, ³Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Nancy University Hospital, Nancy, France, ⁵Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose Remission has become a more achievable goal in rheumatoid arthritis (RA). Several criteria for remission are available in RA, including one based on RAPID3…
Abstract Number: 1868 • 2014 ACR/ARHP Annual Meeting
Can DAS 28 at 3 Months after the 1^st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?
Tomohiro Kubota¹, Syuji Takei², Tsuyoshi Yamatou³, Tomokazu Nagakura⁴, Hiroyuki Imanaka³, Yukiko Nonaka³, Tomoko Takezaki³, Harumi Akaike³ and Mio Matsuura⁵, ¹8-35-1 Sakuragaoka, Kagoshima University Hospital, Kagoshima City, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Kagoshima University, Kagoshima-Shi, Japan
Background/Purpose: To avoid the progression of joint damage, early decision making is important in JIA patients who failed to achieve sustainable clinical remission by…
Abstract Number: 1371 • 2014 ACR/ARHP Annual Meeting
Impact of Metabolic Syndrome (MetS) on Rheumatoid Arthritis Disease Activity
Federico Parra-Salcedo¹, Irazú Contreras-Yáñez², Daniel Elías-López³, Carlos A. Aguilar-Salinas³ and Virginia Pascual-Ramos⁴, ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán., Mexico City, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose The purpose of the study was to describe prevalence and components (c) of MetS in a cohort of early RA, to compare it with…
Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Juan D. Cañete¹, Piotr Leszczynski², Rikke Riisbro³ and Klaus S. Frederiksen³, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, ³Novo Nordisk A/S, Søborg, Denmark
Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…
Abstract Number: 589 • 2014 ACR/ARHP Annual Meeting
Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Lennart TH Jacobsson¹, Tomas Husmark², Elke Theander³, Kenneth Henriksson⁴, Katharina Büsch⁵ and Martin Johansson⁵, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Rheumatology city clinic, Stockholm, Sweden, Stockholm, Sweden, ⁵AbbVie AB, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose The ASAS axial SpA classification criteria was published in 2009 but so far there has been limited research on axial SpA patients in clinical…
Abstract Number: 387 • 2014 ACR/ARHP Annual Meeting
Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Caroline Grönwall¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M. Clancy⁴ and Gregg J. Silverman¹, ¹Medicine, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Monitoring disease activity in patients with autoimmune rheumatic disease is an essential part of clinical care. Highly reactive malondialdehyde (MDA) arise from reactive oxygen…
Abstract Number: L17 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Rheumatoid Arthritis Disease Activity, Reduces Inflammatory Markers, and Decreases Medication Usage
Jeffrey A. Sparks¹, Florencia Halperin², Jonathan C. Karlson³, Elizabeth W. Karlson¹ and Bonnie L. Bermas¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Obesity causes a chronic inflammatory state. Increased body mass index (BMI) is associated with incident rheumatoid arthritis (RA) and may impact RA disease activity.…
Abstract Number: 2973 • 2014 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis
Eric H. Sasso¹, George Wu², CC Hwang², Michael E. Weinblatt³, Nancy A. Shadick⁴, Claire Alexander⁵ and Oscar Segurado¹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ³Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose This study evaluated the association between baseline disease activity, as assessed with the multi-biomarker disease activity (MBDA) blood test, CRP or clinical measures, and…
Abstract Number: 2579 • 2014 ACR/ARHP Annual Meeting
How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? – an Analysis in the DESIR Cohort
Pedro Machado^1,2, Victoria Navarro-Compán^1,3, Robert Landewé^4,5, Floris van Gaalen¹, Christian Roux⁶ and Desirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University College London, London, United Kingdom, ³University Hospital La Paz, Madrid, Spain, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite measure of disease activity in axial spondyloarthritis. It was suggested that when the conventional …
Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…
Abstract Number: 1841 • 2014 ACR/ARHP Annual Meeting
Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, Josh Dixey⁴, Patrick Kiely⁵, David Walsh^6,7 and Adam Young^1,8, ¹School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Institute of Psychiatry, King's College London, London, United Kingdom, ⁴Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁵Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: It is well-established that sustained high disease activity in RA results in worse outcomes. In reality many patients remain in low/moderate disease activity states,…
Abstract Number: 1355 • 2014 ACR/ARHP Annual Meeting
Population Management of Rheumatoid Arthritis (RA) in Rheumatology Practices: A Quality Improvement Project
David Sikes¹, Gary Crump², Kathleen Thomas³, Alex Bangs⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Florida Medical Clinic PA, Zephyrhills, FL, ²Rheumatology Associates - Louisville, Louisville, KY, ³Community Rheumatology, Noblesville, IN, ⁴Crescendo Bioscience, Inc, South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Population management (PM) is required for reducing the burdens of chronic diseases, including RA. PM depends on standardizing disease activity assessment (DAA) and coordinating…
Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Proton Rahman¹, Saeed Shaikh², Michael Starr³, William Bensen⁴, Denis Choquette⁵, Wojciech Olszynski⁶, Maqbool Sheriff⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Susan Otawa¹⁰, Francois Nantel¹¹, Vincent Letourneau¹¹ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²McMaster University, Hamilton, ON, Canada, ³Montreal General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸Université de Montréal, Montreal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].